← Therapeutics
Details checkedClinical trial listing onlyCheckedregistry
Peking postauricular dexamethasone sudden-hearing-loss study
Also known as: Dexamethasone phosphate postauricular injection, NCT02026479
Institution-led study
Sponsor / Institution
Institution-led study
Program Type
Therapeutic
Modality
Steroid/Anti-inflammatory
Stage
Interventional/NA
Status
Unknown
Target Gene
—
Route / Mode
Postauricular injection
Confidence
72%
Status Confidence
Status needs checking
Evidence Strength
Needs more support
Last Reviewed
2026-06-10
Geography
China
Population
adult, sudden, sensorineural, study-level
Trial IDs
1
Mechanism
Randomized institution-led study of low- and high-dose postauricular dexamethasone phosphate injection versus oral Ginaton comparator for full-frequency sudden hearing loss.
Indications
Notes
Split out from the broad dexamethasone cluster. ClinicalTrials.gov verifies a Peking University People's Hospital randomized postauricular dexamethasone study for sudden hearing loss; registry status is Unknown and no commercial sponsor is identified.
Evidence & Sources
1 structured sourcesclinicaltrials
Supports: canonicalName, aliases, company, allCompanies, isIndustrySponsored, programType, modality, mechanism...
IDs: NCT02026479
Key Events
Clinical Trials (1)
Data Checks
institution-led-studyregistry-verified-studygeneric-drug-studycurrent-status-unknown-in-registrystudy-level-not-standalone-productnot-commercial-pipeline-program
Related Programs
Otarmeni by Regeneron
Company: Regeneron Pharmaceuticals · Gene Therapy · Approved
PEDMARK by Fennec Pharmaceuticals
Company: Fennec Pharmaceuticals · Small Molecule · Marketed
AK-OTOF by Eli Lilly and Akouos
Company: Eli Lilly and Company · Gene Therapy · Phase 2
SENS-401 (Arazasetron) by Sensorion
Company: Sensorion · Small Molecule · Phase 2
SENS-501 by Sensorion
Company: Sensorion · Gene Therapy · Phase 1/2
Rincell-1 by Rinri Therapeutics
Company: Rinri Therapeutics · Cell Therapy · Phase 1/2